Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 14.2% in the third quarter, Holdings Channel reports. The firm owned 228,806 shares of the company’s stock after selling 37,978 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Allogene Therapeutics were worth $641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its holdings in shares of Allogene Therapeutics by 429.6% in the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after buying an additional 8,734 shares during the last quarter. Private Advisor Group LLC acquired a new position in Allogene Therapeutics in the 3rd quarter valued at about $34,000. Federated Hermes Inc. purchased a new stake in Allogene Therapeutics during the 2nd quarter valued at approximately $29,000. Algert Global LLC acquired a new stake in Allogene Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Rothschild Investment LLC purchased a new position in shares of Allogene Therapeutics in the 2nd quarter valued at approximately $52,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.87 on Friday. Allogene Therapeutics, Inc. has a one year low of $1.78 and a one year high of $5.78. The company has a market cap of $392.09 million, a P/E ratio of -1.20 and a beta of 0.83. The business has a fifty day moving average of $2.49 and a two-hundred day moving average of $2.57.

Wall Street Analyst Weigh In

ALLO has been the subject of several analyst reports. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler reduced their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).